




CLAREON® PANOPTIX® FACTS YOU CAN TRUST

PanOptix® shows superior image quality (MTF) on the optical bench¹




50%

more image quality (MTF AUC¹) with PanOptix® in the 40 to 66 cm range¹

In a recent clinical study, only 64% of Odyssey* patients reported complete spectacle independence^{2#}

#Based on patient reported questionnaire in a retrospective review with 50 eyes of 25 patients. One-month post-operative assessment.


36% need of spectacles for near tasks



64% complete spectacle independence

Clinical studies show that PanOptix® can achieve 20/20 at distance, intermediate and near, with 20/25 or better in the very near at 33cm^{3+§^}

Mean binocular clinical defocus curve at 3-6 months^{3§} (n=542)



More than 9 out of 10 PanOptix® IOL patients reported NEVER needing glasses at all distances^{5Δ4}



96% at Distance Vision⁴



96% at Intermediate Vision⁴



90% at Near Vision⁴

PANOPTIX IS THE #1 TRIFOCAL IOL WITH MORE THAN 4 MILLION IMPLANTS WORLDWIDE⁵



99.2%

OF PANOPTIX® PATIENTS WOULD HAVE THE SAME LENS IMPLANTED AGAIN (N=127)⁶

*Trademarks are the property of their respective owners. **The Galien Foundation Honors Excellence in Scientific Innovation at 2021 Prix Galien Awards Gala. Available at: <https://www.prnewswire.com/news-releases/the-galien-foundation-honors-excellence-in-scientific-innovation-at-2021-prix-galien-awards-gala-301411801.html>. Accessed December 19, 2023. ¹AUC: Area under the curve. ²Based on pooled analysis of binocular defocus curve at near, intermediate, and distance at 3-6 months (n=547). ³Based on data for AcrySof® IQ PanOptix® Trifocal IOL. AcrySof® IQ PanOptix® is optically equivalent to Clareon® PanOptix®. ⁴Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 Early Treatment Diabetic Retinopathy Study chart letters in the line were identified correctly. ⁵Based on a meta-analysis of 13 studies with a total of more than 600 patients. ⁶Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?"; n=127. ⁷Based on worldwide IOL unit sales of AcrySof® IQ PanOptix®, Clareon® PanOptix® and PanOptix® Pro IOLs, as of Q3, 2025.

Alcon medical device(s) comply with the current legislation for the medical devices. Please refer to relevant products instructions for use for complete list of indications, contraindications and warnings.

1. Alcon Data on File 2024. REF-25451. 2. Bissen-Miyajima H, Midorikawa M, Fujisaki R, Ota Y, Minami K, Honda R. Early Clinical Results of a Newly Developed Continuous Range of Vision Intraocular Lens. Ophthalmol Ther. 2025 Aug 31. 3. Kohonen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical Outcomes After Bilateral Implantation of a Directive Trifocal Intraocular Lens: A Worldwide Pooled Analysis of Prospective Clinical Investigations. Clin Ophthalmol. 2023;17:155-163. 4. Zhu D, Ren S, Mills K, Hull J, Dhariwal M. Rate of Complete Spectacle Independence with a Trifocal Intraocular Lens: A Systematic Literature Review and Meta-Analysis. Ophthalmol Ther. 2023;12(2):1157-1171. 5. Market Scope IOL Report 2024. 6. Modi et al. Visual and Patient-Reported Outcomes of a Directive Trifocal Intraocular Lens Compared with Those of a Monofocal Intraocular Lens. 2020 Sep 28;S0161-6420(20)30677-1.

Danish Court Ruling

The Maritime and Commercial **High Court** in Copenhagen on application from Alcon issued a preliminary injunction on 22 January 2026 against AMO Ireland (a subsidiary of Johnson&Johnson) that currently **prohibits AMO** Ireland from **making the following promotional claims** about TECNIS **Odyssey*** in Denmark:

Range of vision related claims:

- "full visual range IOL unlike any other"
- "Unmatched Range of Vision"
- "17% more AUC"
- "A continuous full range of vision with better near compared to PanOptix®"
- "14% smaller readable print size"
- "Outstanding Range of Vision"
- "The new full visual range IOL offers high-quality and continuous vision with unmatched range"

Contrast related claims

- "Best-in-class contrast"
- "Best-in-class Image contrast"
- "2.4x higher contrast vs. Clareon® PanOptix®"
- "15% higher contrast vs. a leading competitor Monofocal"
- "2.4x higher contrast vs. a leading competitor Trifocal"
- "15% higher image contrast vs. Clareon® monofocal"
- "TECNIS Odyssey* IOL provides better image quality than PanOptix® day and night"

Other claims

- "Optimised Dysphotopsia Profile" or "Optimised dysphotopsia profile"
- "Enhanced Tolerance to Refractive Error"

The preliminary injunction was issued after AMO Ireland confirmed these claims (for commercial and procedural reasons only). A main action on these claims is currently pending between the parties before the same court. The preliminary injunction will remain valid until a decision is issued in the main proceedings. In the preliminary injunction proceedings, AMO Ireland **did not provide supporting evidence** for these claims.

*Trademarks are the property of their respective owners.